See more : Williams Industrial Services Group Inc. (WLMSQ) Income Statement Analysis – Financial Results
Complete financial analysis of Corcept Therapeutics Incorporated (CORT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Corcept Therapeutics Incorporated, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- SRG Mining Inc. (SRGMF) Income Statement Analysis – Financial Results
- PT Suryamas Dutamakmur Tbk (SMDM.JK) Income Statement Analysis – Financial Results
- Fabled Copper Corp. (FABL.CN) Income Statement Analysis – Financial Results
- Xilinx, Inc. (XIX.DE) Income Statement Analysis – Financial Results
- Soho Development S.A. (SHD.WA) Income Statement Analysis – Financial Results
Corcept Therapeutics Incorporated (CORT)
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 482.38M | 401.86M | 365.98M | 353.87M | 306.49M | 251.25M | 159.20M | 81.32M | 50.29M | 26.55M | 10.36M | 3.31M | 0.00 | 0.00 | 29.00K | 209.00K | 482.00K | 294.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 6.48M | 5.39M | 5.28M | 5.58M | 5.50M | 5.22M | 3.55M | 2.06M | 1.36M | 882.00K | 143.00K | 91.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 475.89M | 396.47M | 360.70M | 348.29M | 300.98M | 246.03M | 155.65M | 79.26M | 48.93M | 25.67M | 10.21M | 3.22M | 0.00 | 0.00 | 29.00K | 209.00K | 482.00K | 294.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 98.66% | 98.66% | 98.56% | 98.42% | 98.20% | 97.92% | 97.77% | 97.47% | 97.29% | 96.68% | 98.62% | 97.25% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 184.35M | 130.99M | 113.86M | 114.76M | 89.02M | 75.25M | 40.38M | 23.84M | 15.42M | 18.37M | 20.47M | 14.07M | 21.00M | 18.95M | 14.40M | 14.15M | 7.86M | 20.83M | 17.07M | 11.55M | 8.11M | 13.26M | 5.39M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.33M | 8.49M | 5.88M | 5.75M | 4.87M | 5.04M | 4.08M | 4.49B | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.49B | 0.00 | 0.00 | 0.00 |
| SG&A | 184.26M | 152.85M | 122.36M | 105.33M | 100.36M | 81.29M | 62.42M | 45.24M | 36.95M | 34.92M | 31.24M | 25.41M | 11.33M | 8.49M | 5.88M | 5.75M | 4.87M | 5.04M | 4.08M | 4.49M | 1.89M | 5.53M | 2.62M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.44M | 6.59M | 4.33M | 4.39M | 4.02M | 4.03M | 3.29M | 3.02B | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 368.61M | 283.84M | 236.22M | 220.09M | 189.38M | 156.54M | 102.79M | 69.08M | 52.37M | 53.29M | 51.71M | 39.49M | 32.33M | 27.44M | 20.28M | 19.90M | 12.73M | 25.88M | 21.16M | 16.04M | 9.99M | 18.80M | 8.01M |
| Cost & Expenses | 375.09M | 289.22M | 241.50M | 225.67M | 194.88M | 161.75M | 106.35M | 71.14M | 53.73M | 54.17M | 51.85M | 39.58M | 32.33M | 27.44M | 20.28M | 19.90M | 12.73M | 25.88M | 21.16M | 16.04M | 9.99M | 18.80M | 8.01M |
| Interest Income | 17.28M | 3.56M | 529.00K | 3.40M | 5.07M | 2.66M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 3.56M | 0.00 | 0.00 | 5.07M | 2.66M | 49.00K | 2.04M | 2.97M | 3.76M | 4.52M | 1.78M | 3.00K | 1.50M | 101.00K | 944.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.04M | 2.97M | 3.07M | 2.24M | 2.17M | 236.00K | 106.00K | 87.00K | 155.00K | 141.00K | 74.00K | 27.00K | 3.00K | 6.00K | 10.00K | 12.00K | 13.00K | 14.00K | 704.00K | 1.61M | 22.55K | 0.00 | 0.00 |
| EBITDA | 108.32M | 112.63M | 124.48M | 130.44M | 113.78M | 89.73M | 52.96M | 10.27M | -3.29M | -27.48M | -41.42M | -36.25M | -32.35M | -25.96M | -20.25M | -19.69M | -12.25M | -25.58M | -20.09M | -15.47M | -9.97M | -18.80M | -8.01M |
| EBITDA Ratio | 22.46% | 28.03% | 34.01% | 36.23% | 36.41% | 35.62% | 33.20% | 12.62% | -6.54% | -103.49% | -399.94% | -1,096.01% | 0.00% | 0.00% | -69,734.48% | -8,785.17% | -2,534.44% | -8,693.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 107.28M | 112.63M | 124.48M | 128.20M | 111.61M | 89.50M | 52.86M | 10.18M | -3.44M | -27.62M | -41.50M | -36.27M | -32.33M | -27.44M | -20.25M | -19.69M | -12.25M | -25.58M | -21.16M | -16.04M | -9.99M | -18.80M | -8.01M |
| Operating Income Ratio | 22.24% | 28.03% | 34.01% | 36.23% | 36.41% | 35.62% | 33.20% | 12.52% | -6.85% | -104.02% | -400.66% | -1,096.82% | 0.00% | 0.00% | -69,827.59% | -9,420.57% | -2,540.46% | -8,701.36% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 17.28M | 3.56M | 529.00K | 3.40M | 5.07M | 2.66M | -49.00K | -2.04M | -2.97M | -3.76M | -4.52M | -1.78M | -22.00K | 1.47M | 84.00K | -372.00K | 672.00K | 709.00K | 1.07M | 510.35K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 124.56M | 116.19M | 125.01M | 131.60M | 116.68M | 92.15M | 52.81M | 8.14M | -6.41M | -31.38M | -46.01M | -38.05M | -32.35M | -25.97M | -20.17M | -20.06M | -11.57M | -24.87M | -20.09M | -15.53B | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 25.82% | 28.91% | 34.16% | 37.19% | 38.07% | 36.68% | 33.17% | 10.01% | -12.74% | -118.20% | -444.25% | -1,150.53% | 0.00% | 0.00% | -69,537.93% | -9,598.56% | -2,401.04% | -8,460.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 18.42M | 14.77M | 12.49M | 25.59M | 22.50M | 16.74M | -76.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 22.00K | -1.47M | -84.00K | 372.00K | -672.00K | -709.00K | -1.07M | -510.35K | -182.23K | 18.50M | 7.45M |
| Net Income | 106.14M | 101.42M | 112.51M | 106.01M | 94.18M | 75.41M | 129.12M | 8.14M | -6.41M | -31.38M | -46.01M | -38.05M | -32.35M | -25.97M | -20.17M | -20.06M | -11.57M | -24.87M | -20.09M | -15.53M | -9.81M | -18.50M | -7.45M |
| Net Income Ratio | 22.00% | 25.24% | 30.74% | 29.96% | 30.73% | 30.01% | 81.11% | 10.01% | -12.74% | -118.20% | -444.25% | -1,150.53% | 0.00% | 0.00% | -69,537.93% | -9,598.56% | -2,401.04% | -8,460.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 1.02 | 0.95 | 0.97 | 0.92 | 0.82 | 0.60 | 1.14 | 0.07 | -0.06 | -0.31 | -0.46 | -0.41 | -0.39 | -0.38 | -0.38 | -0.43 | -0.34 | -1.09 | -0.89 | -0.84 | -1.13 | -2.75 | -1.39 |
| EPS Diluted | 0.94 | 0.87 | 0.89 | 0.85 | 0.77 | 0.60 | 1.04 | 0.07 | -0.06 | -0.31 | -0.46 | -0.41 | -0.39 | -0.38 | -0.38 | -0.43 | -0.34 | -1.09 | -0.89 | -0.84 | -1.13 | -2.75 | -1.39 |
| Weighted Avg Shares Out | 103.56M | 106.79M | 115.65M | 115.41M | 114.35M | 125.68M | 113.53M | 110.57M | 106.80M | 100.98M | 99.82M | 93.02M | 83.31M | 68.34M | 52.44M | 46.72M | 34.25M | 22.84M | 22.61M | 18.44M | 8.65M | 6.72M | 5.38M |
| Weighted Avg Shares Out (Dil) | 111.74M | 115.97M | 125.96M | 124.19M | 122.57M | 126.69M | 124.52M | 116.14M | 106.88M | 100.98M | 99.82M | 93.02M | 83.31M | 68.34M | 52.44M | 46.72M | 34.25M | 22.84M | 22.61M | 18.44M | 8.65M | 6.72M | 5.38M |
What Makes Corcept (CORT) a Good Fit for 'Trend Investing'
Corcept (CORT) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Corcept (CORT) Up 19.7% Since Last Earnings Report: Can It Continue?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
Corcept Therapeutics: A Most Promising And Compelling Biotech
Corcept Therapeutics specializes in cortisol-modulating drugs, with Korlym targeting Cushing Syndrome and a promising pipeline, including Relacorilant, for diabetes and ovarian cancer. CORT's robust financials, strong profitability, and near-monopolistic position in a niche market underscore its investment potential despite legal...
Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Corcept Shares Rise More Than 60% in Three Months: Here's Why
CORT's Cushing's syndrome drug, Korlym, is driving revenues. The NDA for relacorilant in Cushing's syndrome will be filed shortly.
3 Reasons Growth Investors Will Love Corcept (CORT)
Corcept (CORT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Wall Street Analysts Think Corcept (CORT) Could Surge 37.91%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 37.9% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an...
Corcept (CORT) is on the Move, Here's Why the Trend Could be Sustainable
Corcept (CORT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article.
5 Small Drug Stocks to Buy as Trump Gets Re-Elected
Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio.
Source: https://incomestatements.info
Category: Stock Reports